LYKALABSNSELyka Labs Limited· PharmaceuticalsLowNeutral
Announced Fri, 1 Aug · 16:13 IST

Lyka Labs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 01, 2025

Board & Shareholder Meetings View source PDF

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Lyka Labs Limited held its 46th Annual General Meeting on August 1, 2025 via video conferencing, attended by 40 members. The meeting was chaired by Mr. Babulal Jain, with Managing Director & CEO Mr. Kunal Gandhi presenting the performance review for FY2024-25. A total of 9 resolutions were put to vote, including adoption of audited financial statements, appointment of Ms. Archana Yadav as Independent Director, re-appointment of Mr. Yogesh Shah as Whole-time Director, approval of related party transactions for FY2025-26, and introduction of the Lyka Labs Limited Employees Stock Option Scheme 2025. Both the Statutory Auditor's and Secretarial Auditor's Reports had no qualifications, observations, or adverse remarks. E-voting results are awaited and will be announced within the prescribed regulatory timeline.

Likely market impact

The AGM proceedings are largely procedural and don't materially impact shareholders, though the introduction of a new ESOP Scheme 2025 could lead to future equity dilution, and approval of related party transactions for FY2025-26 is worth monitoring for any governance concerns.